Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michelle Xia

Showing results (11-20 of 34) with videos related to

Pageof 4
Sort By:
Dermatology and Therapy|September 5, 2023
Safety, Pharmacokinetics and Preliminary Efficacy of IL4-Rα Monoclonal Antibody AK120 in Both Healthy and Atopic Dermatitis Subjects: A Phase I, Randomized, Two-Part, Double-Blind, Placebo-Controlled, Dose-Escalation, First-In-Human Clinical StudyChristopher John Wynne, Alexandra Cole, Charlotte Lemech, et al.
Frontiers in Immunology|July 14, 2022
Penpulimab, an Fc-Engineered IgG1 Anti-PD-1 Antibody, With Improved Efficacy and Low Incidence of Immune-Related Adverse EventsZhaoliang Huang, Xinghua Pang, Tingting Zhong, et al.
Iscience|March 4, 2025
Design of a fragment crystallizable-engineered tetravalent bispecific antibody targeting programmed cell death-1 and vascular endothelial growth factor with cooperative biological effectsTingting Zhong, Lingzhi Zhang, Zhaoliang Huang, et al.
Frontiers in Pharmacology|September 2, 2022
Population pharmacokinetic/pharmacodynamic analysis of AK111, an IL-17A monoclonal antibody, in subjects with moderate-to-severe plaque psoriasisQian Li, Ju Qiao, Hongzhong Jin, et al.
Clinical and Experimental Rheumatology|October 17, 2025
Efficacy and safety of monoclonal antibody AK111 in the treatment of active ankylosing spondylitis: a randomised, double-blind, placebo-controlled, multicentre phase II clinical studyHua Ye, Shengyun Liu, Yongjun Mei, et al.
Cell Reports. Medicine|October 18, 2023
A phase 1a/1b first-in-human study (COMPASSION-01) evaluating cadonilimab in patients with advanced solid tumorsSophia Frentzas, Hui K Gan, Rasha Cosman, et al.
Human Pathology|July 14, 2015
Expression and clinical significance of epidermal growth factor receptor and insulin-like growth factor receptor 1 in patients with ampullary adenocarcinomaMichelle Xia, Michael J Overman, Asif Rashid, et al.
Drug Design, Development and Therapy|April 29, 2025
The Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Subcutaneous Administration of a Novel Anti-NGF Monoclonal Antibody (AK115) in Healthy Participants: A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Phase I Clinical TrialJuan Zhang, Yu-Xin Fan, Yu Huang, et al.
Pharmacological Research|August 7, 2024
Ebronucimab in Chinese patients with hypercholesterolemia---A randomized double-blind placebo-controlled phase 3 trial to evaluate the efficacy and safety of ebronucimabYanyan Zhang, Zhaohui Pei, Beijian Chen, et al.
Frontiers in Immunology|November 9, 2023
The efficacy and safety of cadonilimab combined with lenvatinib for first-line treatment of advanced hepatocellular carcinoma (COMPASSION-08): a phase Ib/II single-arm clinical trialQian Qiao, Chun Han, Sisi Ye, et al.
Pageof 4

Showing results (11-20 of 34) with videos related to

Sort By:
Pageof 4
Dermatology and Therapy|September 5, 2023
Safety, Pharmacokinetics and Preliminary Efficacy of IL4-Rα Monoclonal Antibody AK120 in Both Healthy and Atopic Dermatitis Subjects: A Phase I, Randomized, Two-Part, Double-Blind, Placebo-Controlled, Dose-Escalation, First-In-Human Clinical StudyChristopher John Wynne, Alexandra Cole, Charlotte Lemech, et al.
Frontiers in Immunology|July 14, 2022
Penpulimab, an Fc-Engineered IgG1 Anti-PD-1 Antibody, With Improved Efficacy and Low Incidence of Immune-Related Adverse EventsZhaoliang Huang, Xinghua Pang, Tingting Zhong, et al.
Iscience|March 4, 2025
Design of a fragment crystallizable-engineered tetravalent bispecific antibody targeting programmed cell death-1 and vascular endothelial growth factor with cooperative biological effectsTingting Zhong, Lingzhi Zhang, Zhaoliang Huang, et al.
Frontiers in Pharmacology|September 2, 2022
Population pharmacokinetic/pharmacodynamic analysis of AK111, an IL-17A monoclonal antibody, in subjects with moderate-to-severe plaque psoriasisQian Li, Ju Qiao, Hongzhong Jin, et al.
Clinical and Experimental Rheumatology|October 17, 2025
Efficacy and safety of monoclonal antibody AK111 in the treatment of active ankylosing spondylitis: a randomised, double-blind, placebo-controlled, multicentre phase II clinical studyHua Ye, Shengyun Liu, Yongjun Mei, et al.
Cell Reports. Medicine|October 18, 2023
A phase 1a/1b first-in-human study (COMPASSION-01) evaluating cadonilimab in patients with advanced solid tumorsSophia Frentzas, Hui K Gan, Rasha Cosman, et al.
Human Pathology|July 14, 2015
Expression and clinical significance of epidermal growth factor receptor and insulin-like growth factor receptor 1 in patients with ampullary adenocarcinomaMichelle Xia, Michael J Overman, Asif Rashid, et al.
Drug Design, Development and Therapy|April 29, 2025
The Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Subcutaneous Administration of a Novel Anti-NGF Monoclonal Antibody (AK115) in Healthy Participants: A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Phase I Clinical TrialJuan Zhang, Yu-Xin Fan, Yu Huang, et al.
Pharmacological Research|August 7, 2024
Ebronucimab in Chinese patients with hypercholesterolemia---A randomized double-blind placebo-controlled phase 3 trial to evaluate the efficacy and safety of ebronucimabYanyan Zhang, Zhaohui Pei, Beijian Chen, et al.
Frontiers in Immunology|November 9, 2023
The efficacy and safety of cadonilimab combined with lenvatinib for first-line treatment of advanced hepatocellular carcinoma (COMPASSION-08): a phase Ib/II single-arm clinical trialQian Qiao, Chun Han, Sisi Ye, et al.
Pageof 4